![LOWY: Paylines are dropping because NCI is drawing more applicants who would've previously gone elsewhere](https://cdn.cancerletter.com/media/2019/12/Avalanche-web.jpg)
![LOWY: Paylines are dropping because NCI is drawing more applicants who would've previously gone elsewhere](https://cdn.cancerletter.com/media/2019/12/Avalanche-web.jpg)
Cover Story
After an examination of the causes of an avalanche of grant applications directed at NCI, institute officials found that new applications largely come from principal investigators who are switching their research focus to cancer. No other NIH institute or center faces such pressure.
In Brief
Funding Opportunities
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
NCI Trials
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
![NCI Trials](https://cdn.cancerletter.com/media/2019/05/03161630/CTEP.jpg)
NCI Trials for December 2019
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- Before the Olympics were smoke-free, tobacco brand deals ran rampant
- Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications
- Better oncology drug management could lead to improved outcomes, lower costs
- Tweaking the existing systems is not the answer to drug shortages